Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 26, 2022

BUY
$3.38 - $5.65 $30,605 - $51,160
9,055 Added 36.17%
34,088 $133,000
Q1 2022

Apr 27, 2022

SELL
$5.06 - $8.77 $11,202 - $19,416
-2,214 Reduced 8.13%
25,033 $138,000
Q4 2021

Jan 31, 2022

BUY
$7.33 - $9.32 $199,720 - $253,942
27,247 New
27,247 $232,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Dupont Capital Management Corp Portfolio

Follow Dupont Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Dupont Capital Management Corp with notifications on news.